John Najim
John Najim, MBA, brings over 27 years of experience in clinical and commercial CMC development and manufacture of multiple modalities, including biologics, oligonucleotides, small molecules and antibody drug conjugates.
Most recently as CTO at Dyne Therapeutics, he implemented and executed on the CMC strategy and development of two neuromuscular global supply chains from pre-IND through clinical proof of concept. Previously, he held roles of increasing responsibility at Proteon Therapeutics and Dyax Corporation. Mr. Najim helped guide two BLAs to approval, enabled and managed multiple pivotal clinical development programs and supported over 15 INDs. In addition, Mr. Najim served as a CMC advisory board member and CMC consultant on multiple programs, including support of several start-up and stealth company ventures.
Mr. Najim obtained a BS in biochemistry from Merrimack College, and an MBA from Bentley University.